COVID-19 for Healthcare Providers

2025-26 COVID-19 vaccines are recommended for individuals 6 months and older with healthcare provider consultation (to view comprehensive recommendations, visit the ‘recommendations’ section below). The following COVID-19 vaccines are approved:

• Moderna’s Spikevax (approved for 6 months+) and mNexspike (approved for 12 years+)
• Pfizer-BioNTech’s Comirnaty (approved for 5 years+)
• Novavax’s Nuvaxovid (approved for 12 years+)

COVID-19 vaccines are underutilized. During the 2025-26 respiratory season, only 18.5% of adults received a COVID-19 vaccine with only 31% of adults 65-74 and 37% of those 75+. A healthcare provider’s strong recommendation is a key factor in vaccine acceptance.

• Post-exposure Prophylaxis (medication for preventing COVID-19)
  • Ensitrelvir (Xocova), a preventive oral antiviral for individuals following contact with an someone who has COVID-19. This is indicated for people ages 12 or older within 72 hours following contact with an individual who has COVID-19.
• Pre-exposure Prophylaxis (medication for preventing COVID-19)
  • Pemivibart (Pemgarda), a preventive monoclonal antibody for individuals who are moderately to severely immunocompromised. This is indicated for people ages 12 or older and weigh at least 88 pounds in addition to vaccination. This can be given at least two weeks after vaccination as an IV infusion.

There are several antiviral medications available to treat mild to moderate COVID-19 in individuals at increased risk.